NASDAQ:JSPR Jasper Therapeutics Q3 2026 Earnings Results & Report $11.23 -0.54 (-4.59%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more. Jasper Therapeutics missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$10.19 versus the -$1.77 consensus estimate, while revenue of $8 million topped the $6 million estimate by $2 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 16, 2026TimeBefore Market OpensConference Call8:00 AM ET Jasper Therapeutics EPS ResultsActual EPS-$10.19Consensus EPS -$1.77Beat/MissMissed by -$8.42One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersJasper Therapeutics Revenue ResultsActual Revenue$8 millionExpected Revenue$6 millionBeat/MissBeat by +$2.00 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Jasper Therapeutics Q3 2026 Earnings FAQ Did Jasper Therapeutics beat earnings estimates for Q3 2026? Jasper Therapeutics (NASDAQ:JSPR) reported earnings of -$10.19 per share for Q3 2026, missing the consensus estimate of -$1.77. The report was announced on Monday, November 16, 2026. What was Jasper Therapeutics' revenue for Q3 2026? Jasper Therapeutics reported revenue of $8 million for Q3 2026, against a consensus estimate of $6 million. Jasper Therapeutics Earnings HeadlinesJasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update on Renal Basket Study and Pipeline ProgressNovember 16 at 8:31 AM | quiverquant.comQJasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 16 at 8:00 AM | globenewswire.comPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.November 17 at 1:00 AM | OilPrice (Ad)Jasper Therapeutics (NASDAQ:JSPR) Stock Rating Lowered by Wall Street ZenNovember 14 at 1:25 AM | americanbankingnews.comJasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its WarrantsNovember 9, 2026 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Shares Gap Down - Time to Sell?November 8, 2026 | americanbankingnews.comSee More Jasper Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jasper Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jasper Therapeutics and other key companies, straight to your email. Email Address About Jasper TherapeuticsJasper Therapeutics (NASDAQ:JSPR) is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria. The drug is investigational and is not approved for commercial use. Jasper is based in the United States and conducts clinical-stage drug development. Its programs are intended to address unmet medical needs in areas including rare blood disorders and allergic or inflammatory conditions.View Jasper Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.